South San Francisco
Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.
Estimated valuation today
$157M
-94.29% since last round
Calculated based on estimated multiplier and revenue.
Revenue
Update this based on your knowledge or projections. Calculations use last 12 months revenue.
Hype Multiple
Currently selected comps have a median growth rate of 11.40%
This premium represents how much of a bonus the company receives on its valuation for its additional growth compared to the selected public comps. The valuation is multipled by the Hype Multiple to get the final valuation. You can read more about this from a16z.
multiple
In an event of a merger or aquisition, the investors will get their money back first. In this case, the investors got paid out first and there is no money left which means employee common stock is worthless.
The last round was 8 months ago.
Date
December 2021
Valuation
$2.7B
Amount raised
$290M
We estimate company valuation by comparing it to similiar companies in the public market. The revenue multipler is calculated by taking a company's current valuation and dividing it by its total revenue.
Multiple at last round
1.70x revenue
Today's multiple
1.64x revenue
Change
-3.70%
Companies
Industry – Healthcare
Last updated 5 mins ago.
| Remove | Name | Ticker | Price multiple |
|---|---|---|---|
| Freenome | 1.64x | ||
| 1Life Healthcare Inc | ONEM | 4.38x | |
| HCA Holdings Inc | HCA | 1.04x | |
| Tenet Healthcare Corporation | THC | 0.37x | |
| Quest Diagnostics Incorporated | DGX | 1.51x | |
| Humana Inc | HUM | 0.67x |
| Date | Round | Amount raised | Price per share (Preferred) | Valuation |
|---|---|---|---|---|
| Dec 2021 | Series E | $290MM | $11.67 | $2.74B |
| Dec 2021 | Series D | $300MM | $7.54 | $1.43B |
| Aug 2020 | Series C | $270MM | $6.61 | $927.08MM |
| Jul 2019 | Series B | $165MM | $4.56 | $464.3MM |
| Aug 2017 | Series A | $69.62MM | $3.07 | $196.16MM |
| Jun 2016 | Series Seed-2 | $5.55MM | $0.61 | $25.34MM |
| May 2016 | Series Seed-1 | $800.02K | $0.24 | $2.67MM |
With a revenue of $64M and a Hype Multiple of 1.5x,
Freenome is estimated to be worth $157M.